WIPO has elected two vice-chairs for the GA, Tunisia and Turkey. Tunisia now chairing.
Chile made a very nice statement on the public domain, copyright L&E, and access to knowledge.
The Tunisia chair just ruled that NGOs cannot speak today, and may only submit written statements. We may have opportunity later this week. The excuse was the “long list” of NGOs, but that not true. There were only about 4 or 5 on the list, including KEI, TWN and the WBU.
The following is the statement that the United States asked be included in the record for Agenda item 5 (General Statements) of the 2009 WIPO General Assembly.
AGENDA ITEM 5: General Statements
BACKGROUND:
This is a semi-live blog that will be edited during the day.
It’s Wed, September 23rd, and WIPO is winding up a relatively boring two days of a high level Ministerial segment. Many delegates felt this was poorly organized, with notices going out fairly late, and not much preliminary work or focus. Tomorrow begins the more substantive agenda.
Every year at the end of September, the World Intellectual Property Organization (WIPO) holds a General Assembly (GA). The GA hears reports from all WIPO committees, approves budgets and top staff appointments, and sets the agenda for the next year. This year’s GA started today, with a large number of patent and copyright office heads, trade negotiators and NGOs in attendance.
For several years, the UN Human Rights Council (HRC) has been working on mechanisms to implement a 1986 UN Resolution on the “Right to Development.” To this end, the HRC has created a Working Group on the Right to Development, and a High Level Task Force On The Implementation Of The Right To Development.
This note concerns two areas of policy concerning humanitarian uses of patents. (1), a recommended exception to patent rights for humanitarian uses, and (2), the licensing of patents for humanitarian uses. Both examples focus on access to essential medical technologies.… Continue Reading
On July 6, 2009, a report of the the U.S.-Japan Regulatory Reform and Competition Policy Initiative was presented to President Obama and Prime Minister Aso of Japan. The report provides an insight into the degree that the U.S. government tries to influence prices for medicines and medical devices in foreign markets. Here, as in other foreign markets, the U.S. government seeks to raise prices, and to give industry an even greater role in setting the prices for their products.
According to a report by Duff Wilson in the Sunday New York Times, Much of PhRMA’s $150 million in advertising will be spent pushing Senator Baucus’s version of the health “reform” legislation.
USTR has a system I was not that familiar with. For documents the public can’t see, USTR provides access under an NDA to private sector “experts” they want to consult. On Friday I was told by USTR:
“We’ve consulted with an array of experts from various IP and tech industries and associations and NGOs in the process of deliberation regarding a US proposal on one section of the agreement.”
James K. Glassman and I published an article on biogenerics today in Roll Call. Continue Reading